OverviewSuggest Edit

MolMed is a biotechnology company focused on research, development and clinical validation of novel antitumour therapies. MolMed's pipeline includes two novel therapeutics in clinical development: TK, a cell- based therapy enabling bone marrow transplants from partially compatible donors, in Phase III in high-risk acute leukaemia; NGR-hTNF, a novel vascular targeting agent, in Phase III in malignant pleural mesothelioma and in Phase II in six more indications: colorectal, lung (small-cell and non-small-cell), liver and ovarian cancer, and soft tissue sarcomas. MolMed also offers expertise in cell and gene therapy to third parties to develop, conduct and validate projects from preclinical to Phase III trials, including scale-up and cGMP production of clinical-grade viral vectors, and manufacturing of patient-specific genetically engineered cells. 
TypePublic
Founded1996
HQMilano, IT
Websitemolmed.com

Latest Updates

Employees (est.) (Dec 2017)186
Share Price (Oct 2020)€0.5
Cybersecurity ratingFMore

MolMed Office Locations

MolMed has offices in Milano and Bresso
Milano, IT (HQ)
58 Via Olgettina Milano
Bresso, IT
Via Antonio Meucci, 3
Show all (2)

MolMed Financials and Metrics

MolMed Revenue

Market capitalization (29-Oct-2020)

239.6m

Closing stock price (29-Oct-2020)

0.5
MolMed's current market capitalization is €239.6 m.
Show all financial metrics

MolMed Cybersecurity Score

Cybersecurity ratingPremium dataset

F

56/100

SecurityScorecard logo

MolMed Online and Social Media Presence

Embed Graph

MolMed Blogs

CAR-TCR Summit Europe - February 24 to 27, 2020 in London, United Kingdom

CAR-TCR Summit Europe - 24 - 27 Febbraio 2020 Londra, UK ilaria Mar, 02/25/2020 - 14:32 Il CAR-TCR Summit Europe avrà luogo a Londra, Regno Unito, dal 24 al 27 febbraio 2020. Luca Alberici, Chief Business Officer di MolMed, presenterà giovedì 25 febbario alle ore 15.30 (ora italiana) l'a…

ASGCT Annual Meeting 2019

Scientific Apr 29, 2019 - May 2, 2019 Location:  Washington DC (USA) MolMed at this event:  Presentation: Implementation of iCELLis® Technology for the Manufacture of Lentiviral vectors IT

MolMed l'officina dei superfarmaci

Apr 16, 2019 Page cover:  Il Sole 24 Ore publishes an article on MolMed, in which is described the activities of development and production of gene and cell therapies in its facilities, with an interview with Riccardo Palmisano, Giuliana Vallanti and Michele Manfredini. Attachment:  molmed_sole_…

World Advanced Therapies & Regenerative Medicine Congress Terrapinn

Scientific May 15, 2019 - May 17, 2019 Location:  London, UK MolMed at this event:  Silver Sponsor. Giuliana Vallanti Conference: Friday 17th May 2019 VIRAL VECTOR MANUFACTURE 11:45 TBC: Technology for safe and effective viral vector manufacture Reserved MolMed EN

ARM annual Meeting on the MED

Scientific Apr 23, 2019 - Apr 24, 2019 Location:  Barcelona, Spain MolMed at this event:  PANEL: THE PRICING AND REIMBURSEMENT LANDSCAPE: OPPORTUNITIES AND CHALLENGES Luca Alberici, Ph.D., Chief Business Officer, MolMed EN

CS_Disponibilità verbale assemblea 25.10 e dello Statuto sociale aggiornato

Press release file:  3473_1542389991.pdf Publication Date and time:  Nov 16, 2018 EN
Show more

MolMed Frequently Asked Questions

  • When was MolMed founded?

    MolMed was founded in 1996.

  • How many employees does MolMed have?

    MolMed has 186 employees.

  • Who are MolMed competitors?

    Competitors of MolMed include OncoArendi Therapeutics, Luye Pharma and Dragonfly.

  • Where is MolMed headquarters?

    MolMed headquarters is located at 58 Via Olgettina Milano, Milano.

  • Where are MolMed offices?

    MolMed has offices in Milano and Bresso.

  • How many offices does MolMed have?

    MolMed has 2 offices.